Clinical Signal
FDA signals regulatory flexibility as biotech M&A and IPO activity accelerates
The FDA's recent leadership changes appear to be influencing regulatory decisions, with UniQure moving forward on a gene therapy filing and Moderna's mRNA flu vaccine winning unanimous advisory committee support. Meanwhile, dealmaking remains robust with major acquisitions by Biogen and Lilly, and Kardigan's $400 million IPO marking the fourth biotech this year to raise at least that amount, the strongest showing since 2021.
An FDA advisory committee unanimously endorsed Moderna's mRNA flu vaccine, positioning the company for a dramatic turnaround after the agency declined to review the shot earlier this year. The endorsement marks a significant milestone for Moderna's efforts to expand beyond COVID-19 vaccines.
UniQure's decision to file its Huntington's gene therapy for approval marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad from FDA leadership. Analysts suggest current FDA leadership may be more flexible in certain cases, representing a significant shift in the agency's approach.
Biogen is acquiring RayThera in a $1 billion deal to expand its immune drug portfolio. While the companies did not specify which drugs Biogen is acquiring, patents secured by RayThera provide important clues about the assets involved.
Eli Lilly acquired 4E Therapeutics to add non-opioid pain drugs to its portfolio. The deal is the latest in a string of acquisitions for Lilly, which has invested more than $18 billion in M&A over the past few years.
Heart drug developer Kardigan raised $400 million in its IPO, becoming the fourth biotech in 2026 to raise at least that amount. This marks the most biotechs to achieve this milestone in a single year since 2021, according to BioPharma Dive data.
The biotech launched with $180 million in Series A funding to advance an anti-inflammatory drug for inflammatory bowel diseases that originated with vTv Therapeutics. The company is emphasizing the drug's improved side effect profile compared to existing treatments.
Jazz Pharmaceuticals entered a potentially $4 billion collaboration with AbCellera to develop multispecific T cell engagers. The deal represents the latest effort by drugmakers to broaden the use of T cell engagers beyond their current limited success in certain blood cancers.
Pfizer announced that CFO Dave Denton will step down after taking a job outside the pharmaceutical industry, with a search underway for his successor. Separately, Denali Therapeutics sold a priority review voucher, and a new Duchenne gene therapy received venture backing and a GSK deal.
Vedana Therapeutics emerged from stealth with $46 million in funding to develop anti-PACAP therapies for migraine prevention. The approach represents an increasingly popular strategy in the migraine treatment space.
The convergence of regulatory flexibility, strong capital markets, and active M&A suggests a more favorable environment for drug development and commercialization. Sponsors and CROs should monitor how FDA's evolving posture may create new opportunities for advancing clinical programs.
The Clinical Signal
Published by LINEA System · Curated weekly from public industry sources · Not investment advice
Issue published June 21, 2026 • Next edition next week • Sources linked within each item